209 related articles for article (PubMed ID: 28914153)
1. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
Kim GY; Ahuja T; Papadopoulos J; Cirrone F
J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
3. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
5. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
[TBL] [Abstract][Full Text] [Related]
9. Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
[TBL] [Abstract][Full Text] [Related]
10. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
16. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
[TBL] [Abstract][Full Text] [Related]
17. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
[TBL] [Abstract][Full Text] [Related]
18. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
Lendvai N; Tsakos I; Devlin SM; Schaffer WL; Hassoun H; Lesokhin AM; Landau H; Korde N; Mailankody S; Smith E; Chung DJ; Koehne G; Shah GL; Alexander A; Patel M; Ballagi A; Grundberg I; Giralt SA; Landgren O
Leuk Lymphoma; 2018 Aug; 59(8):1981-1985. PubMed ID: 29308691
[No Abstract] [Full Text] [Related]
20. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR
Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
